• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统评价免疫抑制剂和生物疗法治疗自身免疫性后部葡萄膜炎的疗效。

Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.

机构信息

Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain.

出版信息

Semin Arthritis Rheum. 2011 Feb;40(4):314-23. doi: 10.1016/j.semarthrit.2010.05.008. Epub 2010 Jul 24.

DOI:10.1016/j.semarthrit.2010.05.008
PMID:20656330
Abstract

OBJECTIVES

To analyze the effectiveness of immunosuppressants and biological therapies in autoimmune posterior uveitis, chronic anterior uveitis associated with juvenile idiopathic arthritis, and macular edema.

METHODS

Systematic review. We conducted a sensitive literature search in Medline (from 1961) and EMBASE (from 1980) until October 2007. Selection criteria were as follows: (1) population: autoimmune posterior uveitis, chronic anterior uveitis in juvenile idiopathic arthritis, and macular edema; (2) intervention: immunosuppressive and biologic therapies; (3) outcomes: visual acuity, Tyndall, vitreous haze, macular edema, pars planitis, and retinal vasculitis. There were no limitations regarding study design. The quality of each study was evaluated using the Jadad's scale and Oxford Levels of Evidence.

RESULTS

Two hundred sixty-five articles were selected for detailed review of the 4235 found in the initial search: 128 records were on immunosuppressants, 105 on biological therapies, and 32 on macular edema. Overall, both the immunosuppressive and the biologic therapies appeared effective in the treatment of autoimmune posterior uveitis, except for daclizumab in uveitis related to Behçet's disease, and for etanercept in any uveitis. In the treatment of macular edema, the drugs tested were also effective.

CONCLUSIONS

Based on the evidence collated, immunosuppressants and biological therapies (except for daclizumab in Behçet and etanercept) may be effective in autoimmune uveitis and macular edema. No superiority may be inferred from this review.

摘要

目的

分析免疫抑制剂和生物疗法在自身免疫性后葡萄膜炎、与幼年特发性关节炎相关的慢性前葡萄膜炎和黄斑水肿中的疗效。

方法

系统评价。我们对 Medline(始于 1961 年)和 EMBASE(始于 1980 年)进行了敏感的文献检索,检索截止日期为 2007 年 10 月。选择标准如下:(1)人群:自身免疫性后葡萄膜炎、幼年特发性关节炎的慢性前葡萄膜炎和黄斑水肿;(2)干预措施:免疫抑制和生物治疗;(3)结局:视力、Tyndall 现象、玻璃体混浊、黄斑水肿、脉络膜炎和视网膜血管炎。研究设计没有任何限制。使用 Jadad 量表和牛津证据等级评估每个研究的质量。

结果

在初始搜索中发现的 4235 篇文章中,有 265 篇文章被选中进行详细审查:128 篇关于免疫抑制剂,105 篇关于生物疗法,32 篇关于黄斑水肿。总体而言,免疫抑制剂和生物疗法似乎对自身免疫性后葡萄膜炎的治疗有效,但贝切特氏病相关葡萄膜炎中的达克珠单抗和任何葡萄膜炎中的依那西普除外。在黄斑水肿的治疗中,所测试的药物也有效。

结论

根据汇集的证据,免疫抑制剂和生物疗法(除了贝切特氏病中的达克珠单抗和依那西普)可能对自身免疫性葡萄膜炎和黄斑水肿有效。本综述无法推断出任何优势。

相似文献

1
Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis.系统评价免疫抑制剂和生物疗法治疗自身免疫性后部葡萄膜炎的疗效。
Semin Arthritis Rheum. 2011 Feb;40(4):314-23. doi: 10.1016/j.semarthrit.2010.05.008. Epub 2010 Jul 24.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
6
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.肾移植中新型免疫抑制方案的临床疗效与成本效益:一项系统评价与模型研究
Health Technol Assess. 2005 May;9(21):1-179, iii-iv. doi: 10.3310/hta9210.
7
Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.成人非感染性中间、后和全葡萄膜炎的非生物制剂、皮质类固醇保留疗法。
Cochrane Database Syst Rev. 2022 Oct 31;10(10):CD014831. doi: 10.1002/14651858.CD014831.pub2.
8
Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.非甾体抗炎药与皮质类固醇用于控制单纯性白内障手术后的炎症
Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD010516. doi: 10.1002/14651858.CD010516.pub2.
9
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.依那西普和依法利珠单抗治疗银屑病:一项系统评价。
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
10
Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery.预防性使用非甾体抗炎药预防白内障手术后黄斑水肿。
Cochrane Database Syst Rev. 2016 Nov 1;11(11):CD006683. doi: 10.1002/14651858.CD006683.pub3.

引用本文的文献

1
Anterior and Posterior Ocular Changes in Patients with Active and Inactive Ankylosing Spondylitis.活动期和非活动期强直性脊柱炎患者的眼前部和后部眼部变化
Med Sci Monit. 2025 Jan 9;31:e946834. doi: 10.12659/MSM.946834.
2
Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI.复合眼部炎症活动指数(UVEDAI)的观察者间可靠性及对变化的敏感性
Ophthalmol Ther. 2024 Jun;13(6):1669-1682. doi: 10.1007/s40123-024-00943-w. Epub 2024 Apr 18.
3
Rheumatologist's Perspective on Non-Infectious Uveitis: Patterns from Tertiary Referral Rheumatologic Clinics in Italy.
意大利三级转诊风湿科医师对非感染性葡萄膜炎的观点。
Int J Mol Sci. 2023 Jun 2;24(11):9690. doi: 10.3390/ijms24119690.
4
Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy.接受免疫抑制药物治疗的炎症性肠病患者发生葡萄膜炎的风险。
Crohns Colitis 360. 2020 Jun 4;2(3):otaa041. doi: 10.1093/crocol/otaa041. eCollection 2020 Jul.
5
Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis.UVEDAI的验证:一种评估葡萄膜炎炎症活动水平的指标
Ophthalmol Ther. 2023 Apr;12(2):1045-1055. doi: 10.1007/s40123-023-00654-8. Epub 2023 Jan 23.
6
Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults.成人非感染性中间、后和全葡萄膜炎的非生物制剂、皮质类固醇保留疗法。
Cochrane Database Syst Rev. 2022 Oct 31;10(10):CD014831. doi: 10.1002/14651858.CD014831.pub2.
7
Retinal vasculitis the first clue in the diagnosis of progressive hemifacial atrophy.视网膜血管炎是进行性半侧面部萎缩诊断的首要线索。
Eur J Rheumatol. 2019 May 20;6(4):219-222. doi: 10.5152/eurjrheum.2019.18100.
8
Update in treatment of uveitic macular edema.葡萄膜炎性黄斑水肿的治疗进展
Drug Des Devel Ther. 2019 Feb 19;13:667-680. doi: 10.2147/DDDT.S166092. eCollection 2019.
9
Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.醛酮还原酶:糖尿病和炎症性疾病治疗靶点的多功能蛋白。
Adv Exp Med Biol. 2018;1032:173-202. doi: 10.1007/978-3-319-98788-0_13.
10
Development of an activity disease score in patients with uveitis (UVEDAI).葡萄膜炎患者活动疾病评分(UVEDAI)的制定
Rheumatol Int. 2017 Apr;37(4):647-656. doi: 10.1007/s00296-016-3593-1. Epub 2016 Nov 4.